Related Articles for PubMed (Select 17331261)

Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.

Santos RP, Awa E, Anbar RD.

BMC Pediatr. 2007 Mar 2;7:11.

PMID: 17331261 [PubMed - indexed for MEDLINE]

Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin.

Alothman GA, Alsaadi MM, Ho BL, Ho SL, Dupuis A, Corey M, Coates AL.

Chest. 2002 Sep;122(3):930-4.

PMID: 12226034 [PubMed - indexed for MEDLINE]

Elevated serum tobramycin concentrations after treatment with tobramycin inhalation in a preterm infant.

Abdulhamid I, Wise TL, Andrews S, Biglin K, Lehr VT.

Pharmacotherapy. 2008 Jul;28(7):939-44.

PMID: 18576909 [PubMed - indexed for MEDLINE]

Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis.

Nikolaizik WH, Trociewicz K, Ratjen F.

Eur Respir J. 2002 Jul;20(1):122-6.

PMID: 12166559 [PubMed - indexed for MEDLINE]

Hypersensitivity to inhaled TOBI following reaction to gentamicin.

Spigarelli MG, Hurwitz ME, Nasr SZ.

Pediatr Pulmonol. 2002 Apr;33(4):311-4.

PMID: 11921461 [PubMed - indexed for MEDLINE]

Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.

Cheer SM, Waugh J, Noble S.

Drugs. 2003;63(22):2501-20. Review.

PMID: 14609360 [PubMed - indexed for MEDLINE]

Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis.

Moss RB.

Chest. 2002 Jan;121(1):55-63.

PMID: 11796432 [PubMed - indexed for MEDLINE]

Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.

Drobnic ME, Suñé P, Montoro JB, Ferrer A, Orriols R.

Ann Pharmacother. 2005 Jan;39(1):39-44. Epub 2004 Nov 23.

PMID: 15562142 [PubMed - indexed for MEDLINE]

Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system.

Geller DE, Rosenfeld M, Waltz DA, Wilmott RW; AeroDose TOBI Study Group.

Chest. 2003 Jan;123(1):28-36.

PMID: 12527599 [PubMed - indexed for MEDLINE]

10:

Efficacy and safety of aerosolized tobramycin in cystic fibrosis.

Pai VB, Nahata MC.

Pediatr Pulmonol. 2001 Oct;32(4):314-27. Review.

PMID: 11568993 [PubMed - indexed for MEDLINE]

11:

[Inhalational antibiotic therapy in mucoviscidosis. Apropos of a galenic form of tobramycin]

Sermet-Gaudelus I, Hubert D, Turck D.

Arch Pediatr. 2001 Dec;8 Suppl 5:884s-893s. French. No abstract available.

PMID: 11811055 [PubMed - indexed for MEDLINE]

12:

A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.

Chuchalin A, Csiszér E, Gyurkovics K, Bartnicka MT, Sands D, Kapranov N, Varoli G, Monici Preti PA, Mazurek H.

Paediatr Drugs. 2007;9 Suppl 1:21-31.

PMID: 17536872 [PubMed - indexed for MEDLINE]

13:

Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.

Lenoir G, Antypkin YG, Miano A, Moretti P, Zanda M, Varoli G, Monici Preti PA, Aryayev NL.

Paediatr Drugs. 2007;9 Suppl 1:11-20.

PMID: 17536871 [PubMed - indexed for MEDLINE]

14:

Optimal tobramycin dosage in patients with cystic fibrosis--evidence for predictability based on previous drug monitoring.

Bartel K, Habash T, Lugauer S, Bärmeier H, Böwing B, Unsal M, Schoerner C, Heininger U.

Infection. 1999;27(4-5):268-71.

PMID: 10885841 [PubMed - indexed for MEDLINE]

15:

Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.

Bilton D, Henig N, Morrissey B, Gotfried M.

Chest. 2006 Nov;130(5):1503-10.

PMID: 17099030 [PubMed - indexed for MEDLINE]

16:

A pilot study to compare tobramycin 80 mg injectable preparation with 300 mg solution for inhalation in cystic fibrosis patients.

Nikolaizik WH, Vietzke D, Ratjen F.

Can Respir J. 2008 Jul-Aug;15(5):259-62.

PMID: 18716688 [PubMed - indexed for MEDLINE]

17:

Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.

Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C.

Pediatr Pulmonol. 2007 Apr;42(4):307-13.

PMID: 17352404 [PubMed - indexed for MEDLINE]

18:

Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency.

Edson RS, Brey RH, McDonald TJ, Terrell CL, McCarthy JT, Thibert JM.

Mayo Clin Proc. 2004 Sep;79(9):1185-91.

PMID: 15357042 [PubMed - indexed for MEDLINE]

19:

Microbiological and immunologic considerations with aerosolized drug delivery.

LiPuma JJ.

Chest. 2001 Sep;120(3 Suppl):118S-123S.

PMID: 11555566 [PubMed - indexed for MEDLINE]

20:

Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis.

Rosenfeld M, Gibson R, McNamara S, Emerson J, McCoyd KS, Shell R, Borowitz D, Konstan MW, Retsch-Bogart G, Wilmott RW, Burns JL, Vicini P, Montgomery AB, Ramsey B.

J Pediatr. 2001 Oct;139(4):572-7.

PMID: 11598606 [PubMed - indexed for MEDLINE]

Recent Activity